Q3 FY2026 · ended Sep 30, 2026 · Revenue $832.50M, +4.1% YoY · Filed Nov 4, 2026
United Therapeutics Corporation (UTHR) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $832.5 million and net income of $258.6 million. Free cash flow was $125.8 million.
Revenue
$832.50M
+4.1% vs year-ago quarter
Net income
$258.60M
-23.6% vs year-ago quarter
Operating cash flow
$306.50M
-45.5% vs year-ago quarter
Free cash flow
$125.80M
-64.2% vs year-ago quarter
EPS
$5.71
-20.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
42.59M
-1.1% vs year-ago quarter
Net cash
—
Operating margin
41.4%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- UTHR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Silver Spring, MD
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1082554
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $832.5M | $783.3M | $781.5M | $790.2M | $799.5M |
| Operating income | $307.8M | $330.8M | $325.8M | $356.7M | $388.5M |
| Net income | $258.6M | $333.0M | $274.9M | $364.3M | $338.7M |
| Diluted EPS | $5.71 | $7.27 | $5.82 | $7.70 | $7.16 |
| Operating cash flow | $306.5M | $313.6M | $463.3M | $346.2M | $562.1M |
| Free cash flow | $125.8M | $205.6M | $362.5M | $173.3M | $351.6M |
| Total assets | $7.0B | $7.2B | $6.7B | $7.9B | $7.4B |
| Total liabilities | $758.1M | $819.8M | $813.1M | $783.8M | $760.9M |
| Stockholders' equity | $6.3B | $6.4B | $5.9B | $7.1B | $6.6B |
| Cash and investments | $3.5B | $3.8B | $3.5B | $4.7B | $4.3B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Other events
|
Oct 22, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Other events
|
Oct 14, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
All 1002 United Therapeutics Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.